**Core tip:** Our study shows that hepatic artery infusion chemotherapy (HAIC) with either TOMOX (oxaliplatin plus raltitrexed) or FOLFOX (oxaliplatin plus 5-fluorouracil) was proven to be an efficient and safe alternative choice for patients with chemotherapy refractory colorectal cancer liver metastasis and no significant difference in survival was found between these two treatments. Cox univariate analysis shows that response to HAIC was a significant predictive factor.

INTRODUCTION
============

Colorectal cancer is the third leading cause of cancer death and has the third leading incidence of new cases in Western countries\[[@B1]\]. The situation in China is similar; there were 376.3 thousand new colorectal cancer cases in 2015, and colorectal cancer was the fifth leading cause of cancer death\[[@B2]\]. Approximately 30%-50% of patients develop liver metastasis, and no more than 20% of liver metastasis patients are candidates for liver resection\[[@B3],[@B4]\]. Chemotherapy is the primary treatment for advanced colorectal cancer. The efficiency and survival benefit of standard first- or second-line systemic therapy have been improved by the combination of targeted therapy\[[@B5],[@B6]\], and the overall survival (OS) after effective first-line therapy is nearly 30 mo\[[@B7]-[@B9]\]. However, the survival of chemotherapy refractory patients, who failed previous systemic treatment, is expected to improve. Third-line chemotherapy could result in an OS period of 9.3 mo\[[@B10]\]. Alternative treatments, such as transarterial chemoembolization (TACE) and hepatic artery infusion chemotherapy (HAIC), are greatly needed.

HAIC with FOLFOX \[oxaliplatin plus 5-fluorouracil (5-Fu)\] in patients with CRCLM has also been demonstrated as a feasible and low-toxicity treatment, with a local overall disease control rate of 50%-79.2%\[[@B11],[@B12]\]. However, 5-Fu should be administered intra-arterially for approximately 44 h, and a higher incidence of catheter thrombosis and catheter-associated infection is reported\[[@B13]\]. As a specific inhibitor of thymidylate synthase, raltitrexed has been used in CRC patients and could be infused in approximately 1 h. Several previous studies have shown that TOMOX (oxaliplatin plus raltitrexed) showed efficiency similar to other traditional first-line treatments in CRC patients and was associated with less neutropenia and gastrointestinal toxicity and uncommon cardiotoxicity\[[@B14]-[@B16]\]. However, studies concerning HAIC with TOMOX are rare. Khouri et al\[[@B3]\] examined 17 patients who underwent HAIC with TOMOX, and the treatment was demonstrated as a safe alternative choice. The goal of this retrospective study was to report a head-to-head study comparing the TOMOX and FOLFOX arms in CRCLM patients treated at our center.

MATERIALS AND METHODS
=====================

Study design and patient population
-----------------------------------

From May 2013 to April 2015, 42 patients were treated with oxaliplatin-based HAIC at our center. All of the patients were histologically confirmed with colorectal adenocarcinoma with unresectable liver metastasis and failed two lines of systemic chemotherapy. The treatment criteria for HAIC were: ECOG performance status no more than 2 points; life expectancy ≥ 3 mo; tumor involvement less than 70% of liver volume; and adequate liver and renal dysfunction (total bilirubin serum levels \< 3 mg/dL, serum albumin level \> 20 g/L, and serum creatinine level \< 2 mg/dL). Patients with extrahepatic metastases were included if their main lesion remained in the liver.

Operative technique
-------------------

The Seldinger technique was used to access the femoral artery after the achievement of local anesthesia. Then, arteriography was routinely performed prior to chemoembolization to gather information for the abdominal aorta and celiac trunk. Subsequently, a coaxial catheter (Renegade Hi Flo, Boston Scientific, United States/Stride ASAHI INTECC, Japan) was inserted into the hepatic artery and subsegmental arteries. According to tumor stain, Spongostan particles (Jinling, Nanjing, China) and iodized oil (Lipiodol; Laboratoire Andre Guerbet, Aulnaysous- Bois, France) mixed with 20-40 mg epirubicin hydrochloride (Main Luck Pharmaceutical, Shenzhen, China) were injected. The temporary indwelling catheter was inserted into the hepatic artery until the end of HAIC. HAIC was performed *via* the catheter with oxaliplatin (Hengrui Medicine Co., Ltd., Jiangsu, China) administered at 85 mg/m^2^ in 4 h, 5-Fu (Jinyao aminoacid Co., Ltd., Tianjing, China) administered at 2000 mg/m^2^ in approximately 44 h, CF (Hengrui Medicine Co., Ltd. Jiangsu China) administered at 200 mg/m^2^ in 2-4 h *via* the peripheral vein, and raltitrexed (Tianqing Pharmaceutical Co., Ltd., Nanjing, China) administered at 3 mg/m^2^ in approximately 1 h. At the end of perfusion, the catheter was removed every cycle.

HAIC was regularly applied every 3 wk, until the patient died or liver function was Child-Pugh C or disease progressed. Enhanced computed tomography or magnetic resonance imaging and laboratory tests were regularly performed, and all patients were followed until death or loss to follow-up. Objective response rate (ORR) was evaluated using Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1, and adverse reactions were evaluated using Common Terminology Criteria for Adverse Events (CTCAE) 2.0. Peripheral neuropathy was graded according to a modified Levi Scale.

Statistical analysis
--------------------

OS after diagnosis was calculated from the date of diagnosis of CRC to the date of death or last follow-up time, OS after first HAIC was calculated from the date of first HAIC to the date of death or last follow-up time, and PFS was calculated from the date of the initiation of therapy to the date of disease progression. A biomedical statistician conducted the statistical review in the present study. The SPSS software program (version 19; SPSS, Chicago, Illinois) was used for the analyses. GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA) was used to generate the charts. For all tests, a *P* value \< 0.05 was defined as significant. Student's *t*-test was used to analyze continuous variables. These variables were reported as the means ± SD if normally distributed or as a median and range if skewed. The *χ*^2^ test was used to analyze categorical variables. These variables were reported as a proportion (%) of the overall cohort. The Kaplan-Meier method was used to approximate the PFS and OS, and the significance of survival differences between the TOMOX and FOLFOX arms was determined using the log-rank test.

RESULTS
=======

Patient characteristics
-----------------------

There were 18 patients in the TOMOX arm and 24 patients in the FOLFOX arm. The baseline characteristics of the patients are shown in Table [1](#T1){ref-type="table"}. The baseline demographics were similar between the two treatment groups, with no significant imbalances in sex, age, primary tumor site, time of liver metastasis, KRAS mutation rate, extrahepatic metastasis, or additional radiofrequency ablation. Patients in the TOMOX arm received a median of 2.2 cycles of treatment, and those in the FOLFOX arm received a median of 2.1 cycles of treatment.

###### 

Summary of patient baseline characteristics

                                         **Overall cohort (*n* = 42)**   **TOMOX (*n* = 18)**   **FOLFOX (*n* = 24)**   ***P* value**
  -------------------------------------- ------------------------------- ---------------------- ----------------------- ---------------
  Gender                                                                                                                0.700
  Male                                   29                              13                     16                      
  Female                                 13                              5                      8                       
  Age at first TACE (yr)                 59 ± 10.7                       60 ± 9.1               58 ± 11.8               0.473
  Primary tumor site                                                                                                    0.601
  Right hemicolon                        10                              5                      5                       
  Left hemicolon                         32                              19                     13                      
  Time to liver metastasis                                                                                              0.508
  Synchronous                            28                              11                     17                      
  Metachronous                           14                              7                      7                       
  Primary tumor grade                                                                                                   0.639
  Poor                                   6                               3                      3                       
  Well to moderate                       36                              15                     21                      
  Genetic condition                                                                                                     0.459
  KRAS mutation                          8                               5                      3                       
  KRAS wild type                         21                              8                      13                      
  Unknown                                13                              5                      8                       
  Extrahepatic metastasis                                                                                               0.927
  Present                                27                              12                     15                      
  Absent                                 15                              6                      9                       
  Combined with other local treatments                                                                                  0.209
  Yes                                    10                              6                      4                       
  No                                     32                              12                     20                      

Efficacy and toxicity
---------------------

With a median follow-up period of 18 mo, the OS after the first HAIC in the FOLFOX and TOMOX arms was 15.4 and 20.6 mo (*P* = 0.734), respectively. The PFS in the FOLFOX and TOMOX arms was 6.6 and 4.0 mo (*P* = 0.215), respectively (Figure [1](#F1){ref-type="fig"}). The response rates of the two different treatment groups are shown in the Table [2](#T2){ref-type="table"}. The overall response rate was 29.2% in the FOLFOX arm and 11.1% in the TOMOX arm, and no significant difference was observed between the FOLFOX and TOMOX groups (*P* = 0.158).

![Kaplan-Meier curves showing the survival data after hepatic artery infusion chemotherapy. The median survival time of the TOMOX arm was 20.6 mo (curve A), and that of the FOLFOX arm was 15.4 mo (curve B).](WJG-23-1406-g001){#F1}

###### 

Response evaluation *n* (%)

  **Response**          **Treatment group**   ***P* value**   
  --------------------- --------------------- --------------- -------
  Partial response      7 (29.2)              2 (11.1)        0.158
  Stable disease        14 (58.3)             11 (61.1)       0.856
  Progressive disease   3 (12.5)              5 (27.8)        0.734

Cox univariate analysis (Table [3](#T3){ref-type="table"}) showed that the response to HAIC was a predictive factor for prognosis. However, age, histology grade, primary tumor site, serum tumor markers, and extrahepatic metastasis showed no significance as predictive factors.

###### 

Predictors of overall survival

  **Factor**                                            **Univariate analysis**                 
  ----------------------------------------------------- ------------------------- ------------- -------
  TOMOX/FOLFOX                                          0.877                     0.410-1.876   0.736
  Male sex                                              0.915                     0.411-2.035   0.827
  Age (\> 60/60 yr)                                     0.758                     0.353-1.627   0.477
  Histology (poor/well and moderate)                    1.768                     0.686-4.554   0.238
  Primary tumor site (left/right hemicolon)             0.715                     0.285-1.797   0.476
  Serum CA19-9 (high/normal)                            1.725                     0.803-3.706   0.162
  Serum CA72-4 (high/normal)                            1.325                     0.536-3.278   0.542
  Serum CEA (high/normal)                               1.339                     0.463-3.873   0.590
  Extrahepatic metastasis (present/absent)              1.220                     0.550-2.706   0.624
  Time to liver metastasis (synchronous/metachronous)   1.281                     0.560-2.932   0.558
  Response to TACE                                                                              0.047
  PD                                                    1.000                     1.000         
  SD                                                    0.275                     0.081-0.931   
  PR                                                    0.272                     0.095-0.783   

All patients were evaluated for toxicity. The toxicity of the two groups is shown in Table [4](#T4){ref-type="table"}. The most common adverse events were transient elevation of serum liver enzymes and bilirubin and abdominal pain. The transient elevation of serum liver enzymes was more frequent in the TOMOX arm than in the FOLFOX arm (100% *vs* 79%, *P* = 0.039). Hematologic adverse events were more frequent in the FOLFOX arm than in the TOMOX arm (leukopenia: 16% *vs* 50%, *P* = 0.026; anemia: 39% *vs* 46%, *P* = 0.212; and thrombocytopenia: 44% *vs* 54%, *P* = 0.533). No significant differences were observed in fever, asthenia, nausea and vomiting and neuropathy between these two treatment groups. Treatment associated cardiotoxicity was not observed in either group. One treatment-related death, diagnosed as neutropenic sepsis, occurred in the FOLFOX arm. No treatment-related death was observed in the TOMOX arm.

###### 

Observed toxicity according to common terminology criteria for adverse events grading *n* (%)

  **Adverse event**            **TOMOX (*n* = 18)**   **FOLFOX (*n* = 24)**   ***P* value**             
  ---------------------------- ---------------------- ----------------------- --------------- --------- -------
  Hematological                                                                                         
  Anemia                       7 (39)                                         11 (46)                   0.212
  Leucopenia                   3 (16)                                         12 (50)         1 (4)     0.026
  Neutropenia                  1 (5)                                          6 (25)          1 (4)     0.094
  Thrombocytopenia             8 (44)                                         13 (54)         3 (12)    0.533
  Nonhematological                                                                                      
  Elevation of liver enzymes   18 (100)               9 (50)                  19 (79)         7 (29)    0.039
  Elevation of bilirubin       17 (94)                3 (17)                  23 (95)         4 (17)    0.834
  Nausea/vomiting              14 (78)                                        17 (71)                   0.839
  Asthenia                     13 (72)                                        12 (50)                   0.414
  Neuropathy                   5 (28)                                         7 (29)          1 (4)     0.921
  Pain                         14 (78)                7 (39)                  19 (79)         13 (54)   0.914
  Fever                        6 (33)                                         11 (46)                   0.558

DISCUSSION
==========

Without an efficient treatment, systemic chemotherapy refractory patients show a median OS of 3.5 mo\[[@B17]\]. HAIC has been demonstrated as an alternative choice for advanced CRC patients. Most studies report the efficiency and survival data of HAI with FOLFOX, while reports concerning HAI with TOMOX are rare. Raltitrexed has been demonstrated as a considerable first-line treatment for patients with advanced CRC. Herein, we present the first head-to-head study comparing HAI with TOMOX or FOLFOX in systemic chemotherapy refractory CRC patients.

The median OS after first HAIC in the present study was 15.4 mo in the FOLFOX arm and 20.6 mo in the TOMOX arm, which was favorable compared with that of the third-line systemic chemotherapy, which achieved a median OS of 9.3 mo\[[@B10]\]. When TOMOX was used as a first-line treatment, the ORR was 16%-50%, and the median PFS was 5-11 mo\[[@B18]-[@B20]\]. Among all patients in the present study who failed in previous systemic chemotherapy, the ORR (11.1%) and median PFS (4.9 mo) were relatively low. The ORR in the FOLFOX arm was 29.2% with a median PFS of 6.6 mo, consistent previous studies\[[@B11],[@B21],[@B22]\]. Similarly, the median OS of 15.4 mo in the present study is consistent with the 11 and 18.3 mo reported in two previous studies\[[@B11],[@B21]\].

The most common adverse events were the transient elevation of serum liver enzymes and bilirubin and abdominal pain. These common adverse events could be sufficiently controlled by efficient treatments. Similar to previous studies, the incidence of leukopenia grade was significantly higher in the FOLFOX arm, and the elevation of transient hepatic enzymes was significantly higher in the TOMOX arm. The TOMOX arm had no treatment- related deaths, while the FOLFOX arm had one case of neutropenic sepsis. These findings suggest that HAIC with TOMOX could represent tolerable treatments for refractory CRC patients. Survival predictor analysis suggested that early tumor response is a meaningful predictor for patients receiving oxaliplatin-based HAIC. Other factors, including age, primary tumor site, and serum tumor markers, did not show significant difference, partly reflecting the limited sample size in the present study.

The limitation of the present study is a single-center retrospective study with a limited sample size. We could not avoid some bias for the evaluation of clinical outcome and the incomplete patient data. However, the present study was the first to compare the efficiency, survival data, and toxicity of HAIC with TOMOX and FOLFOX in advanced CRC patients, and the results will provide new directions for clinical practice.
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Although liver metastasis develops in approximately 30%-50% of colorectal cancer patients, efficient treatments for advanced colorectal cancer are rare. Third-line chemotherapy confers only a survival period of 9.3 mo. Alternative treatment, such as hepatic artery infusion, is greatly needed. Previous studies have shown that hepatic artery infusion with oxaliplatin and 5-Fu is a safe and efficient choice for these patients; however, 5-Fu should be administered intra-arterially for approximately 44 h and is associated with a higher incidence of catheter thrombosis and infection. Raltitrexed, which could be infused in one hour, is a specific inhibitor of thymidylate synthase and has been reported as an efficient agent in colorectal cancer.
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The authors propose that hepatic artery infusion with raltitrexed and oxaliplatin (TOMOX) is a safe and efficient treatment for patients with colorectal cancer liver metastasis. Herein, we provide support for this hypothesis, showing similar response rates and survival data between the FOLFOX and TOMOX arms.
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Previous studies have shown that raltitrexed is a considerable first-line treatment for patients with advanced colorectal cancer. The present study is the first head-to-head study comparing hepatic artery infusion (HAI) with TOMOX or FOLFOX in systemic chemotherapy refractory colorectal cancer patients.
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Patients with colorectal cancer liver metastasis who failed systemic chemotherapy were treated with hepatic artery infusion with TOMOX or FOLFOX.
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HAI chemotherapy is designed to improve the chemotherapy benefits for liver cancer by increasing the amount of chemotherapy delivered to the site of the tumor. Chemotherapy is dispensed from a specialized infusion system in which a catheter is placed into the hepatic artery to directly deliver the chemotherapy to the liver.
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